Literature DB >> 30896838

Construction of ceRNA networks reveals differences between distal and proximal colon cancers.

Wenwei Qian1, Yifei Feng1, Jie Li1, Wen Peng1, Qiou Gu1, Zhiyuan Zhang1, Dongjian Ji1, Qingyuan Wang1, Dongsheng Zhang2, Yueming Sun2.   

Abstract

Although colon cancer is often referred to as a homogeneous entity, an increasing number of studies have revealed that colon cancer can be divided according to the anatomic site of the cancer. However, few studies have reported the difference between distal and proximal colon cancer with regard to molecular mechanism, and especially non‑coding RNA molecules. In the present study, the data of 186 colon tumour tissues and 17 adjacent non‑tumour colon tissues in the left colon and 229 colon tumour tissues and 21 adjacent non‑tumour colon tissues in the right colon were obtained from The Cancer Genome Atlas (TCGA). A total of 879 lncRNAs, 165 miRNAs and 2,028 mRNAs were identified as left‑specific RNAs [log2(fold change)>2, FDR<0.01]. There were 916 lncRNAs, 227 miRNAs and 2,069 mRNAs identified in right colon cancer. The Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathways were analysed for 2,028 mRNAs from left colon cancer and 2,069 mRNAs from right colon cancer. After removing the elements of the intersection from side‑specific lncRNAs of the left and right, we identified specific lncRNAs included exclusively in left or right colon cancer, including 277 lncRNAs in left colon cancer and 314 lncRNAs in right colon cancer. Among these lncRNAs, 20 lncRNAs from the left and 25 lncRNAs from the right were revealed to be associated with overall survival. Then, ceRNA networks were constructed. There were 18 lncRNAs, 22 miRNAs and 57 mRNAs included in the left colon cancer ceRNA network and 21 lncRNAs, 27 miRNAs and 55 mRNAs included in the right ceRNA network. In total, 15 lncRNAs were revealed to be significantly related to clinical features, two of which were ascertained by testing the mRNA expression of tissues. In conclusion, our research aimed to detect the difference between colon cancer in the left and the right colon and to assist in the identification of new potential biomarkers to be used for diagnostic and prognostic purposes.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30896838     DOI: 10.3892/or.2019.7083

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

1.  Identifying the tumor location-associated candidate genes in development of new drugs for colorectal cancer using machine-learning-based approach.

Authors:  Tuncay Bayrak; Zafer Çetin; E İlker Saygılı; Hasan Ogul
Journal:  Med Biol Eng Comput       Date:  2022-08-10       Impact factor: 3.079

2.  Evaluation of cfDNA as an early detection assay for dense tissue breast cancer.

Authors:  Mouadh Barbirou; Amanda A Miller; Erik Gafni; Amel Mezlini; Asma Zidi; Nathan Boley; Peter J Tonellato
Journal:  Sci Rep       Date:  2022-05-19       Impact factor: 4.996

3.  Construction of a novel mRNA-miRNA-lncRNA network and identification of potential regulatory axis associated with prognosis in colorectal cancer liver metastases.

Authors:  Chen Lu; Xiagang Luo; Cheng Xing; Yonghuan Mao; Yuting Xu; Wenjie Gao; Wulin Wang; Tian Zhan; Guoguang Wang; Zhengxia Liu; Chunzhao Yu
Journal:  Aging (Albany NY)       Date:  2021-06-03       Impact factor: 5.682

4.  Prognostic lncRNAs, miRNAs, and mRNAs Form a Competing Endogenous RNA Network in Colon Cancer.

Authors:  Qian-Rong Huang; Xin-Bin Pan
Journal:  Front Oncol       Date:  2019-08-06       Impact factor: 6.244

5.  RNA-Associated Co-expression Network Identifies Novel Biomarkers for Digestive System Cancer.

Authors:  Zheng Chen; Zijie Shen; Zilong Zhang; Da Zhao; Lei Xu; Lijun Zhang
Journal:  Front Genet       Date:  2021-03-26       Impact factor: 4.599

6.  Prognosis prediction model based on competing endogenous RNAs for recurrence of colon adenocarcinoma.

Authors:  Li Peng Jin; Tao Liu; Fan Qi Meng; Jian Dong Tai
Journal:  BMC Cancer       Date:  2020-10-07       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.